Imperial Peptides Q3 2026 Update | UK Peptides Research

Expanding Our UK Peptides Catalogue

Q3 saw another addition to the Imperial Peptides research catalogue with the introduction of PT-141 10mg.

Our approach to catalogue expansion remains selective. Rather than continually increasing the number of products available, we focus on additions that complement the existing research range while maintaining our standards around documentation, testing and traceability.

New Batch Releases & COA Updates

Independent testing and batch documentation continued throughout Q3, with two new batch-specific Certificates of Analysis added to our public COA library.

For researchers comparing UK peptides suppliers, access to batch-specific documentation provides an additional layer of transparency when reviewing research materials.

Our available Certificates of Analysis remain publicly accessible through the Imperial Peptides COA library.

Bacteriostatic Water Supply Restored

In our Q2 update, we reported disruption to Bacteriostatic Water supply following the ongoing Hospira shortage and changes affecting imports.

During Q3, we successfully completed our supplier transition and secured a new source, restoring availability of Bacteriostatic Water 10ml through Imperial Peptides.

Maintaining continuity of supply was important, but not at the expense of our standards. The transition was completed with continued emphasis on product verification, quality control and supply-chain traceability.

Securing the new supplier closes an important operational project from Q2 and gives us a more stable foundation for Bacteriostatic Water availability going forward.

Tesamorelin Research Returns to Imperial Peptides

Q3 also saw GHRH (1–44) Analog Amide 5mg become available directly through Imperial Peptides, bringing Tesamorelin research back into our main catalogue.

Consolidating the product within the main Imperial Peptides store makes it easier for researchers to access the product alongside our wider peptides UK catalogue and associated research documentation.

Introducing Research Peptide Bundles

Another Q3 development was the launch of our new Research Peptide Bundles collection.

Selected research products are now available together with an automatic 3% bundle saving, creating a simpler way to order pre-selected combinations from the Imperial Peptides catalogue.

The introduction of bundles is part of our wider effort to improve the purchasing experience while keeping individual product information, batch documentation and research-use-only positioning clear.

Building Trust in the Peptides UK Market

Q3 was less about rapidly expanding the catalogue and more about strengthening the infrastructure around it.

Restoring Bacteriostatic Water supply, expanding our public COA library, bringing Tesamorelin research directly onto Imperial Peptides and introducing a simpler bundle system all contribute to the same objective: creating a more reliable and transparent research purchasing experience.

As Imperial Peptides continues to grow, our focus remains on clear documentation, independent testing, product traceability and consistent communication with researchers.